Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Royalty PharmaFRA:RPD -2.69%72 3-1 Month Momentum % is 16.86% as of Jul. 31, 2026. GuruFocus rates FRA:RPD with a GF Score™ of 72/100 and a GF Value™ of €33.37 (Significantly Overvalued). The stock has 10 warning signs investors should review. Among 1,389 Biotechnology companies, Royalty Pharma ranks better than 77.11% on this metric.
3-1 Month Momentum % is the total return of the stock from 3-month ago to 1-month ago. As of today (2026-07-31), Royalty Pharma's 3-1 Month Momentum % is 16.86%.
The industry rank for Royalty Pharma's 3-1 Month Momentum % or its related term are showing as below:
FRA:RPD's 3-1 Month Momentum % is ranked better than 77.11% of 1389
companies
in the Biotechnology industry
Industry Median: -7.65
vs FRA:RPD: 16.86
Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 3-1 Month Momentum % measures the total return to a stock over the past three months, but ignores the previous month.
The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.
Royalty Pharma 3-1 Month Momentum % Related Terms
FRA:RPD vs ROIV, INCY, INSM: 3-1 Month Momentum % Comparison
For the Biotechnology subindustry, Royalty Pharma's 3-1 Month Momentum %, along with its competitors' market caps and 3-1 Month Momentum % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Royalty Pharma 3-1 Month Momentum % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Royalty Pharma's 3-1 Month Momentum % distribution charts can be found below:
* The bar in red indicates where Royalty Pharma's 3-1 Month Momentum % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Royalty Pharma (FRA:RPD) has a 3-1 Month Momentum % of 16.86% as of Jul. 31, 2026. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on Royalty Pharma and its competitors. According to the industry distribution chart, Royalty Pharma ranks #318 out of 1389 companies in the Biotechnology industry, placing it in the top 22.9%.
Is Royalty Pharma's 3-1 Month Momentum % too high?
Royalty Pharma's current 3-1 Month Momentum % is 16.86%. Based on the distribution chart, Royalty Pharma ranks #318 out of 1389 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Royalty Pharma has a GF Score™ of 72/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Royalty Pharma's 3-1 Month Momentum % compare to ROIV and INCY?
According to the Biotechnology industry distribution chart, Royalty Pharma ranks #318 out of 1389 companies for 3-1 Month Momentum %. This places Royalty Pharma in the top 23% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-1 Month Momentum % for a Biotechnology company?
A good 3-1 Month Momentum % depends on the Biotechnology industry context. However, 3-1 Month Momentum % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-1 Month Momentum % mean?
A high 3-1 Month Momentum % can signal that a stock is expensive relative to its fundamentals. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on Royalty Pharma and its competitors. Royalty Pharma's current 3-1 Month Momentum % is 16.86%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Royalty Pharma stock overvalued right now?
Based on GuruFocus' analysis, Royalty Pharma (FRA:RPD) is currently considered Significantly Overvalued. The stock's GF Value™ is €33.37, compared to a current price of €50.01 — trading 49.9% above its estimated fair value. The current 3-1 Month Momentum % is 16.86%. Royalty Pharma's overall GF Score™ is 72/100 with 10 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-1 Month Momentum % calculated?
3-1 Month Momentum % is calculated from a company's financial statements. For Royalty Pharma (FRA:RPD), the current 3-1 Month Momentum % is 16.86% as of Jul. 31, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Royalty Pharma (FRA:RPD) Overvalued in 2026?
Based on GuruFocus' analysis, Royalty Pharma stock appears to be overvalued.
The current stock price of €50.01 is trading 49.9% above its estimated GF Value™ of €33.37.
GuruFocus considers Royalty Pharma to be Significantly Overvalued.
Key valuation signals for FRA:RPD:
3-1 Month Momentum %: 16.86%
GF Value™: €33.37 vs. price of €50.01 (49.9% above fair value)
No single metric tells the full story. See the FRA:RPD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.
72GF Score
Get the complete analysis for FRA:RPD
3-1 Month Momentum % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:RPD has been successfully added to your 
